Biofrontera Past Earnings Performance
Past criteria checks 0/6
Biofrontera's earnings have been declining at an average annual rate of -10.9%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 17.5% per year.
Key information
-10.9%
Earnings growth rate
47.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 17.5% |
| Return on equity | -420.0% |
| Net Margin | -59.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%
Dec 30
The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%
Nov 13Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?
Oct 18Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours
Oct 05Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation
Sep 06Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance
Aug 12Biofrontera announces 2Q prelim product revenues
Jul 12Revenue & Expenses BreakdownBeta
How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | -20 | 38 | 0 |
| 30 Sep 23 | 34 | -26 | 38 | 0 |
| 30 Jun 23 | 29 | -23 | 36 | 0 |
| 31 Mar 23 | 28 | -14 | 36 | 0 |
| 31 Dec 22 | 29 | -1 | 35 | 0 |
| 30 Sep 22 | 28 | -12 | 24 | 0 |
| 30 Jun 22 | 28 | -26 | 33 | 0 |
| 31 Mar 22 | 29 | -29 | 29 | 0 |
| 31 Dec 21 | 24 | -38 | 26 | 0 |
| 30 Sep 21 | 24 | -23 | 32 | 0 |
| 30 Jun 21 | 22 | -10 | 19 | 0 |
| 31 Mar 21 | 19 | -10 | 17 | 0 |
| 31 Dec 20 | 19 | -11 | 18 | 0 |
| 31 Dec 19 | 26 | -11 | 28 | 0 |
Quality Earnings: BFRI is currently unprofitable.
Growing Profit Margin: BFRI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BFRI is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare BFRI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BFRI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: BFRI has a negative Return on Equity (-420.01%), as it is currently unprofitable.